BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $151
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $78 to $151.
BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $78 to $151.